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Late cardiopulmonary complications
in breast cancer patients following combined adjuvant treatment
Anna Niwiƒska1, Tadeusz Pieƒkowski1, Ma∏gorzata Tacikowska2, Zbigniew MiÊkiewicz2,
Witold Stelmaszczyk2, Ewa Wasilewska-TeÊluk3
A i m. The aim of the study was to evaluate late toxicity from heart and lungs in breast cancer patients treated with mastecto-
my and adjuvant sequential chemotherapy and radiotherapy (Chth and Rt).
M a t e r i a l  a n d  m e t h o ds. Forty seven women (mean age 47 years) with stage T1-4N0-2 M0 breast cancer, treated with ma-
stectomy and adjuvant sequential chemotherapy and radiotherapy were examined in order to assess the side-effects in the he-
art and the lungs. All patients underwent chemotherapy: 40 received chemotherapy including antracyclines, 7- without antra-
cyclines. Radiotherapy was undertaken in all cases. It was administered after chemotherapy and was planned according to the
well-established technique. It included the chest wall and regional lymph nodes with a specified dose of 46-50 Gy administe-
red in daily fractions of 2Gy. The high resolution computed tomography HRCT of the lungs was performed after a mean ti-
me of 17 (13-28) months and then, after a mean time of 33 (28-58) months. The condition of the heart was studied using elec-
trocardiography (ECG) and echocardiography (ECHO), which were performed before combined treatment and then after
a mean time of 17 and 33 months from its completion.
Re s u l t s. Heart: 7 patients had an abnormal echocardiogram (ventricular dilatation, abnormal Left Ventricular Ejection Frac-
tion, disordered left ventricular contractility, worsening of pre-existent valvular disease). All 7 had received chemotherapy in-
cluding antracyclines. In 5 of them the echocardiographic defects were asymptomatic and reversible during the time of obse-
rvation. In 2 patients moderate toxicity was observed. The analysis of isodose distribution excluded radiotherapy as a factor
influencing toxicity, but seems to indicate a connection with antracyclines.
Lungs: The first examination (after a mean time of 17 months) revealed no changes in 24 patients. There were 19 fibrotic
changes in lung apex and 19 cases of parietal fibrosis. In the second examination (after a mean time of 33 months), there we-
re no changes in 24 patients and 22 fibrotic changes in lung apex and 13 cases of parietal fibrosis. All these changes were di-
screte, asymptomatic and the parietal fibrosis was invisible in the chest X-rays. The analysis of the evolution of fibrotic
changes revealed that parietal fibrosis had a tendency to regression, but the apical ones are unpredictable: some of them do re-
gress, but others – progress. The probability of parietal fibrosis did not depended on type of chemotherapy (p=0.64), but signi-
ficantly depended on the depth of 50% isodose in the lung (p<0.05).
C o n c l u s i o n s. Postoperative radiotherapy as an element of combined adjuvant treatment in breast cancer, administered in
conventional fractionated doses, causes no clinically significant lesions in the lungs and heart. The analysis of the distribution
of isodoses in the heart showed, that clinically important myocardial changes, observed in two patients, were not connected
with radiotherapy. Probably, they were connected with epirubicin chemotherapy. Correctly planned postoperative radiothera-
py is a safe therapeutic method causing no significant disturbances of the functions of vital organs during the mean follow-up
period of 33 months.
Ocena póênych powik∏aƒ ze strony serca i p∏uc u chorych na raka piersi
po skojarzonym leczeniu uzupe∏niajàcym
C e l. Celem pracy by∏a ocena póênej toksycznoÊci ze strony serca i p∏uc u chorych na raka piersi po mastektomii oraz uzupe∏-
niajàcej chemioterapii i radioterapii.
M a t e r i a ∏  i m e t o d a. Badaniu poddano 47 kobiet (Êrednia wieku 47 lat) z rakiem piersi w stopniu zaawansowania
T1-4 N0-2 M0. Po mastektomii, u wszystkich chorych przeprowadzono chemioterapi´ i radioterapi´. U 40 zastosowano
programy z antracyklinami, u 7 – bez antracyklin. Radioterapi´ przeprowadzono wed∏ug tej samej techniki, po zakoƒczeniu
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Introduction
Present treatment of breast cancer is based on a combina-
tion of available methods. The principle of adjuvant the-
rapy after mastectomy is presently the use of chemothera-
py combined with radiotherapy. While the usefulness of
chemotherapy has never been questioned, the role of po-
stoperative radiotherapy has been subject to controversy
over many years. However, three recent reports of con-
trolled studies confirmed the beneficial effects of well
performed postoperative radiotherapy. In the Danish stu-
dy [1] of high risk for local or regional recurrence preme-
nopausal women it was shown that radiotherapy redu-
ced that risk from 32% to 9% (p=0.001) and increased
10-year survival from 45% to 54%. Similar results were
obtained also in postmenopausal women in whom radio-
therapy reduced that risk from 35% to 8% and increased
10-year survival from 36% to 45% (p=0.001) [2]. In the
Canadian controlled study postoperative radiotherapy
reduced the risk of local and regional recurrences from
25% to 13% and improved total 10-year survival from
56% to 65% [3].
However, combined treatment is associated with hi-
gher early and late toxicity. This is particularly true of
radiotherapy combined with anthracyclines. Only scant
data is available on late reactions to anthracyclines in do-
ses used in adjuvant treatment, but it is known that they
potentiate cardiac damage induced by radiotherapy [4].
Presently our objectives include not only possible
cure, but also adequate quality of life of the patients and,
in view of this, the proportion of late complications of
this treatment has become an important problem in mo-
dern oncology. Our interest should be focused on late
sequelae of combined treatment. This is particularly im-
portant in the case of combined treatment with radio-
therapy and anthracyclines and/or taxoids.
Study aim
The aim of the study was to assess the late toxicity of
combined postoperative treatment using chemotherapy
and radiotherapy in patients with breast cancer. Late to-
xic effects were assessed in the heart and lungs.
Material and methods
The prospective study began in November 1996. The study gro-
up comprised 47 patients with breast cancer in stage T1-4, NO-
-2, MO. Their mean age was 47 years (range 31 – 68 years). In 26
patients the right breast and in 21 the left breast was involved.
The indication to adjuvant treatment, pre- and /or postoperati-
ve, was tumour size T3, T4 or G3 and/or involvement of at least
four lymph nodes in the axilla. Forty patients received chemothe-
rapy with anthracacyclines according to the following program-
mes: 1) 4 courses of epirubicin and 4 courses of CMF (cyclopho-
sphamide, methotrexat, 5-fluorouracil); 2) EC (epirubicin, cyc-
lophosphamide); 3) AC (doxorubicin, cyclophosphamide); 4)
CMF (cyclophosphamide, methotrexate, 5-fluorouracil). Seven
patients received chemotherapy without anthracyclines: 6 co-
urses of CMF. Radiotherapy was administered after chemothe-
rapy, after a mean interval of 24 days. All patients received ra-
diotherapy according to the technique proposed by the Maria
Sklodowska-Curie Memorial Cancer Centre and Institute of
Oncology in Warsaw. The modern system planning was used
before treatment in all patients. After marking out the area of ir-
leczenia chemicznego. Napromieniono Êcian´ klatki piersiowej i okolice w´z∏owe (46-50 Gy / 2Gy). W celu oceny zmian w p∏u-
cu, po stronie leczonej, zastosowano badanie tomograficzne komputerowe o wysokiej rozdzielczoÊci HRCT, które przeprowa-
dzono po Êrednim czasie 17 miesi´cy (13-28) i 33 miesi´cy (28-58) od zakoƒczenia leczenia skojarzonego. W celu oceny ser-
ca zastosowano badanie EKG i echokardiograficzne, które przeprowadzono przed rozpocz´ciem leczenia skojarzonego,
a nast´pnie po Êrednim czasie 17 i 33 miesi´cy od jego zakoƒczenia.
W y n i k i. Serce: U 7 chorych (wszystkie leczone antracyklinami) stwierdzono nieprawid∏owoÊci w echokardiogramie (posze-
rzenie i zaburzenie kurczliwoÊci lewej komory, obni˝enie LVEF, nasilenie istniejàcych wad serca). U 5 z nich zmiany by∏y bez-
objawowe i odwracalne. U 2 chorych stwierdzono klinicznie jawnà, miernie nasilonà niewydolnoÊç serca, która wydawa∏a si´
mieç zwiàzek z podanà epirubicynà. Na podstawie analizy rozk∏adu izodoz wykluczono napromienianie jako przyczyn´
zmian w sercu.
P∏uca: W badaniu po Êrednim czasie 17 miesi´cy u 24 pacjentek obraz p∏uc by∏ prawid∏owy. U 19 stwierdzono zw∏óknienia
w szczycie p∏uca po stronie napromienianej, a u 19 zw∏óknienia przyÊcienne. W kolejnym badaniu po Êrednim czasie 33 mie-
si´cy u 24 chorych nie by∏o zmian w p∏ucach, u 22 stwierdzono zw∏óknienia w szczycie i u 13 - zw∏óknienia przyÊcienne. Zmia-
ny by∏y ma∏o nasilone, bezobjawowe i niewidoczne w konwencjonalnym zdj´ciu rentgenowskim klatki piersiowej. Zw∏óknie-
nia przyÊcienne mia∏y tendencj´ do regresji w czasie. Zw∏óknienia w szczycie p∏uca, u cz´Êci chorych ulega∏y regresji, u innych
– progresji. Prawdopodobieƒstwo pojawienia si´ zw∏óknienia nie mia∏o zwiàzku z typem chemioterapii (p=0,64), a zale˝a∏o
od g∏´bokoÊci izodozy 50% w p∏ucu (p<0,05).
W n i o s k i. Radioterapia pooperacyjna, w dawkach konwencjonalnych, nie powodowa∏a klinicznie znaczàcych zmian
w p∏ucu ani sercu. Klinicznie jawne nieprawid∏owoÊci ze strony serca, stwierdzone u 2 chorych, nie mia∏y zwiàzku z radiote-
rapià, lecz mog∏y mieç zwiàzek z epirubicynà. Dotychczasowa obserwacja chorych pozwala przypuszczaç, ˝e prawid∏owo za-
planowana radioterapia pooperacyjna jest bezpiecznà metodà leczenia.
Key words: breast cancer, side-effects, late normal tissue injury, cardiotoxicity, high resolution computed tomography,
echocardiography, antracyclines, radiotherapy
S∏owa kluczowe: rak sutka, objawy uboczne, uszkodzenie tkanek zdrowych, kardiotoksycznoÊç, echokardiografia, antra-
cykliny, radioterapia
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radiation on a simulator, computed tomography slices were per-
formed to assess the target volume and topography of critical or-
gans. The plans of treatment were made using three-dimmentio-
nal computed treatment planning system Helax. The dose-volu-
me histograms in lung and heart were analysed before the start
of irradiation. The depth of the isodose 50% in heart and lung
was measured in 7 computed tomography slices, in every pa-
tient. The irradiated areas were: supraclavicular, posterior axil-
lary, sternal and scar area. Fractions of radiation were conventio-
nal: 2 Gy / day. The beam and administered doses were typical:
Co-60 or photons 4-6 MeV, 50 Gy in 25 fractions to the suprac-
lavicular area; 50 Gy to the axillary area calculated in the depth
of the axilla from the supraclavicular and posterior axillary fields;
the sternal area and the scar area were irradiated with electrons
of individually chosen energy (6-18MeV), in 46 Gy/80% dose.
The mean time of radiotherapy was 51 days. Excluded from the
study were patients who received incomplete doses, or were not
given irradiation to all node areas, who received fraction dose
over 2 Gy, who received irradiation to chest wall from two obli-
que fields, or who had not been given chemotherapy. After lite-
rature review [5] sequential treatment mode was chosen with
radiotherapy beginning 2-4 weeks after completion of chemothe-
rapy. The material is presented in Table I.
Table I. Material
No of cases 47
Age (years) 31-68 (mean 47)
Breast: right 26
left 21
Stage T1N1M0-T4N2M0
II 26
III 21
Chemotherapy: with antracyclines 40
without antracyclines 7
H e a r t . The condition of the heart was studied using electrocar-
diography (ECG) and echocardiography (ECHO). The examina-
tions were carried out before combined treatment and then
after over one year and over two years from its completion. The
first control examination was carried out after a mean time of 17
months (13-28 months), the second one after a mean time of 33
months (28-58 months). In the echocardiographic examination
attention was paid to: pericardium, dimensions of atria, ven-
tricles and aorta, appearance of valves, blood flow across the
ostia, thickness of heart walls and septum, contractility of ventric-
les, end-diastolic and end-systolic pressure in left ventricle, left
ventricular ejection fraction (LVEF), ventricular relaxation. The
authors intended to answer the question, whether possible car-
diac function disturbances were due only to chemotherapy, on-
ly to radiotherapy or the combination of these methods. On the
basis of pertinent literature we assumed that segmental con-
tractility disorders and/or ischaemia of the anterior wall and
septum were the results of toxic effects of radiotherapy. Chemo-
therapy could lead to contractility disturbances of the whole
left ventricle and disordered valvular function [6]. Literature
reports on disturbances in valves and in high ventricular volume
after radiotherapy concerned exclusively patients with Hodg-
kin disease, and could not be used for comparison with breast
cancer because of a different radiotherapy technique and high
heart volume in irradiation area [7].
L u n g s. Late postradiation lesions of the lungs take the form of
fibrosis, mostly on pulmonary apex after photon beam irradiation
and on scar area, near the chest wall, after electron beam. For
the evaluation of fibrosis grade and volume of fibrotic changes
high resolution computed tomography (HRCT) was applied.
The first examination was carried out after a mean time of 17
months (13-28 months) and the second one after a mean time of
33 months (28-58 months) after completion of chemotherapy
and radiotherapy. The purpose of these examinations was an
evaluation of the incidence and dynamics of fibrotic changes in
the lungs and establishing whether radiation-induced pulmona-
ry lesions lead to clinical symptoms and affect the physical con-
dition of the patients. It was also attempted to assess whether the
technique of electron beam treatment expressed as the depth of
50% isodose in pulmonary tissue could influence the develop-
ment of late radiation-induced lesions. The degree of fibrotic le-
sions was assessed using the classification of the work of M.
Overgaard [8], presented in Table II. The degree of fibrosis was
established comparing the involved pulmonary area with the
same area in healthy lung.
S t a t i s t i c a l  a n a l y s i s
To compare the percentage of fibrosis in irradiated lung after
a mean time 17 and 33 months, the Mc Nemar test was used. To
find out whether the lung fibrosis depended on type of chemo-
therapy (with or without antracyclines), the chi square (Yates'
modification) test was used. To assess whether the percentage of
lung fibrosis depends on the depth of isodose 50%, nonparame-
tric test Ko∏omogarow-Smirnow was used.
Results
H e a r t
In 7 out of 47 patients echocardiographic changes were
disclosed after a mean time of 17 months after comple-
tion of chemotherapy and radiotherapy. Six patients we-
re treated according to the programme: 4 courses of epi-
rubicin and 4 courses of CMF, one patient received 4
EC courses and 3 AC courses. Five patients received ra-
diotherapy to the right breast and two to the left. In two
patients the changes involved cardiac valves and were
diagnosed already before treatment beginning (aortic
Table II. Classification of the intensity of late radiation-induced reactions in lung
(from M. Overgaard. Radiat Oncol 1987; 9:1-12)
Grade Late reactions
0 No changes
1 Mild changes: slight, tiny, scattered fibrous densities in exposed area
2 Moderate changes: evident, more confluent fibrotic densities in exposed area with slight retraction of surrounding lung tissue
3 Severe changes: confluent, irregular densities in exposed area with definite retraction of surrounding lung tissue
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regurgitation and mitral regurgitation), and during first
year after chemotherapy and radiotherapy, reversible
worsening on valvular condition was noted. In five pa-
tients impairment of left ventricular contractility was ob-
served in the form of global hypokinesis or relaxation
disturbances. In one of them, after 13 months, fresh aor-
tic regurgitation was noted – clinically important but re-
gressing after treatment with angiotensin convertase in-
hibitors (ACE) after 27 months. In five patients echocar-
diographic changes were clinically silent and were
reversed during treatment with ACE inhibitors. In two
patients moderately intense toxicity with cardiac failu-
re, NYHA grade II, was observed after 18 months and 22
months, and the symptoms persisted during the second
control examination without evidence of progression in
later examination 31 and 34 months after treatment with
perindopril. One of these patients had received radio-
therapy to the left breast, the other one to the right bre-
ast. Both had been treated according to the program-
me: 4 epirubicin and 4 CMF courses. In both cases the
total dose of epirubicin was 400 mg/m2. In both patients
dilatation of the left ventricle was found with global hy-
pokinesis and LVEF decrease, while ECG showed ischa-
emia of anterior and lateral cardiac walls. In one patient
with evidence of ischaemia in ECG in the anterior wall,
coronarography was performed with normal findings.
No segmental disorders of left ventricular contractility
were found, which are typically observed in radiation-
-induced lesions. The analysis of the distribution of isodo-
ses excluded radiotheraphy as a factor influenced car-
diotoxicity in all seven cases, and in two patients with
clinically manifest cardiac failure the heart was comple-
tely outside the radiation rage. In two cases these re-
sults suggested a possible connection between epirubicin
treatment and cardiotoxicity. These results are presented
in Table III and IV.
L u n g s
High resolution computed tomography (HRCT) perfor-
med after a mean time of 17 months from completion of
adjuvant treatment failed to show any changes of the type
of postradiation fibrosis in 24 out of 47 patients. In four
patients slight changes were present in the apex of the
lung (exposed to photon beam from supraclavicular field),
in four patients slight parietal fibrotic changes in middle
Table III. Characteristics of seven patients
with abnormalities in echocardiography examinations
Chemotherapy: 4x epirubicin + 4x CMF* 6 patients
4 x EC** + 4 x AC*** 1 patient
Radiation dose not significant:
Isodose 50% – outside heart
Isodose 20% – <10% of the heart 5 patients
Heart outside radiation range 2 patients
Heart function disturbances:
Disordered left ventricular contractility and one new  valvular heart disease 5 patients
Worsening of pre-existant valvular disease 2 patients
Improvement after ACE inhibitor treatment 7 patients
Legend: * CMF - cyclophosphamide, methotrexate, fluorouracil
** EC - epirubicin, cyclophosphamide
*** AC - doxorubicin, cyclophosphamide
Table IV. Characteristics of two patients with abnormal echocardiography findings without connection
with radiotherapy but with possible connection with chemotherapy
Patient 1 Patient 2
Breast side Right Left
Chemotherapy:
4x epirubicin + 4x CMF*
Total dose of epirubicin 400 mg/m2 400 mg/m2
Radiotherapy:
Heart volume in radiation range Heart outside radiation range Heart outside radiation range
ECG Lowered V1-V3 Lowered V3-V6
ECHO LVEF – 53% LVEF – 51%
Global hypokinesis Global hypokinesis, left ventricular dilatation,
No segmental contractility disturbances No segmental contractility disturbances
Radioisotope ventriculography LVEF – 54% LVEF – 48%
Coronarography Normal Not performed
Legend: *CMF- cyclophosphamide, methotrexate, fluorouracil
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lobe, near the chest wall (exposed to electron beam from
scar area irradiation), and in 15 patients changes were
present in the apex and at the chest wall. In summary,
there were 19 events in the lung apex and 19 events near
the chest wall. Parietal lesions were very slight and invo-
lved only a small lung area, fibrosis was also barely discer-
nible and delicate, without lung tissue retraction, in the
grade I of progression. They were not visible on any co-
nventional radiograms. Their presence depended on the
distribution of isodoses in the lungs. In clinical examina-
tions they could not be detected, produced no symptoms,
and were insignificant from the standpoint of survival
comfort.
After a mean period of 33 months radiation-induced
fibrosis was again studied. HRCT failed to show any chan-
ges in 24 patients. Somewhat more frequently apical chan-
ges were found in the lungs exposed to radiation (22 vs. 19
in the first examination). The results are presented in Ta-
ble V. The analysis of the progression of the changes
(from stage 0 to 1 or from stage 1 to 2) showed in the gro-
up with apical changes, progression in eight cases and
regression in four cases. The analysis of the percent of the
changes in lung apex in examination I and II was not sta-
tistically significant (Mc Nemar' Test p=0.549). In pa-
tients with parietal changes, progression was not obse-
rved during the follow-up, while the parietal lesions indu-
ced by electron beam underwent regression more
frequently (6 cases). These differences were statistically si-
gnificant (Mc Nemar' Test p=0.031)
For evaluation of the intensity of radiation-induced
lesions in the lung, conventional radiograms of the lungs
were obtained in all cases, beside HRCT. The analysis of
the results showed that parietal fibrosis was never detec-
table, while in eight cases apical changes were found.
No statistically significant relationship was noted be-
tween the percent of postradiation fibrosis in the lungs
and the type of adjuvant chemotherapy with or without
anthracyclines (chi square Test p=0.64). In the group of
40 patients treated with antracyclines,  the fibrotic chan-
ges were noted in 21 cases and in the group of 7 patients
treated with CMF, they were detected in 3 cases.
For assessing the relationship between the dose di-
stribution in the scar and parasternal area and lung fi-
brosis, the depth of isodose 50% was analysed in this
area. In the examination I, in 28 patients without parietal
fibrosis, the mean depth of isodose 50% was 1 cm, on
average 0-2 cm, and in 19 patients with detectable fibrosis
- the mean depth was 1.9 cm (range 0.5-4 cm). This diffe-
rence is statistically significant (Ko∏omogarow-Smirnow
Test p<0.05). This observation is important from the
standpoint of planned treatment, since in these cases re-
duction of electron energy, with maintenance of satisfac-
tory dose distribution in the target, should be conside-
red.
Discussion
H e a r t  a n d  r a d i o t h e r a p y
Clinically manifested, adverse effects on the heart are
rare events. Literature data on cardiac mortality after
radiotherapy was published years ago and was related
to radiotherapy techniques no longer used. Their cause
was damage to myocardial fibres, myocardial fibrosis,
damage to small vessels and coronary arterial narrowing
[7, 9-13]. Clinically it is manifested as ichaemic heart di-
sease. The risk of damage depends on the volume of the
part of the heart exposed to radiation, type of radiation,
size of inlet field, total and fraction doses [7, 9, 10, 14-16].
Radiotherapy to the left side of the chest wall, especially
with photons from oblique fields, caused more heart da-
mage (7.9%) than electron beam therapy and/or right
chest side irradiation (3.3%) [7, 12, 14, 17]. Consequen-
tly, ischaemic heart disease develops after years [14]. In
a Swedish study using scintigraphic method Gyenes fo-
und, that asymptomatic ischaemic heart disease was 25%
more frequent in breast cancer patients receiving radio-
therapy to the left breast [7]. Radiotherapy to the left
chest side carried out by previous techniques produced
damage to three important coronary arteries: left ante-
rior descending, left circumflex, and right coronary arte-
ry [12]. Modern radiotherapy methods allow to resolve
this problem in most cases, but in certain patients it is not
possible to avoid exposure of the left anterior descen-
ding artery, and, less frequently, a part of the left main
coronary artery [12, 18]. Damage to these arteries leads
to ischaemia of the anterior wall of the left ventricle,
septum and heart apex [6, 13].
The best way of evaluating radiotherapy-induced
cardiotoxicity is perfusion scintigraphy using technetium
or thallium, or coronarography, since both these me-
thods allow to assess myocardial blood flow [7, 9, 15].
Irreversible myocardial perfusion defects do not necessa-
rily indicate ischaemic heart disease, but can indicate
Table V. Assessment of fibrosis in irradiated lung in Examination I after a mean period
of 17 months and Examination II after a mean period of 33 months in 47 patients
Examination I Examination II
13-28, mean 17 months 25-58, mean 33 months
Time of fibrosis detection (mean in months) 17 33
Normal findings 24 – (51%) 24 – (51%)
Apical fibrosis 4 – (8.5%) 10 – (21%)
Parietal fibrosis 4 – (8.5%) 1 – (2%)
Apical and parietal fibrosis 15 – (32%) 12 – (26%)
Total 47 – (100%) 47 – (100%)
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myocardial fibrosis after radiotherapy. Such patients ha-
ve no symptoms of coronary artery disease [9]. Echocar-
diography permits an assessment of ventricular contrac-
tility, myocardial blood flow and the condition of valves.
This method is more applicable after chemotherapy, but
can also demonstrate segmental left ventricular contrac-
tility disturbances typical of radiotoxicity [7, 19].
The present study was carried out in patients rece-
iving 2 Gy fractions to the chest wall from electron beam.
Irradiation from oblique fields, especially combined with
chemotherapy, is not recommended by the Centre of On-
cology in Warsaw. We paid special attention to the correct
planning of radiotherapy, using modern equipment and
methods.
H e a r t  a n d  c h e m o t h e r a p y
The problem of combined treatment deserves much mo-
re attention, especially in the case of anthracyclines. Do-
xorubicin directly damages myocardial fibres, and car-
diomyopathy and congestive heart failure induced by it
depend on the cumulated dose [12, 16, 20]. Risk factors
for cardiac damage by doxorubicin are: total cumulated
dose, old age, history of heart diseases, previous irradia-
tion of heart area or mediastinum, concomitant treat-
ment with paclitaxel or trastuzumab [16]. Circulatory fa-
ilure caused by doxorubicin develops weeks or months
after treatment, mostly after total doses exceeding
550 mg/m2 [12, 16, 20], although heart failure was repor-
ted after doxorubicin dose 40 mg/m2 [20]. The relative
risk of heart damage is 0.1% after low doses, 7% after
550 mg/m2 dose, and about 50% after cumulative dose
1000 mg/m2 [11, 12, 20]. In adjuvant treatment of breast
cancer patients the total dose is 200 – 360 mg/m2 which
can give 0.1-1% risk of heart failure development [12]. In
the Boston study Shapiro et al. evaluated the risk of car-
diovascular complications in 299 patients after radiothe-
rapy receiving adjuvant chemotherapy by AC programme
(doxorubicin and cyclophosphamide) [14]. The risk of
damage was tree to four times higher in patients rece-
iving doxorubicin in 450 mg/m2 total dose as compared to
those given 225 mg/m2 total dose. A correlation was also
observed between the heart volume in radiation area and
the risk of heart damage.
In the study of cardiotoxicity degree by echocardio-
graphy, Zambetti found abnormalities in 8% of cases,
such as left ventricular ejection fraction after doxorubicin,
and 1% after treatment with cyclophosphamide, metho-
trexate and 5-flourouracil [19].
Cardiomyopathy develops in 3% of women treated
with trastuzumab, but if it is used in combination with
doxorubicin cardiotoxicity rate rises to 18% [16].
No significant adverse effects have been observed
after standard cyclophosphamide doses [20]. CMF pro-
gramme could potentiate cardiotoxicity if administered
after radiotherapy to the mediastinum or after previous
treatment with doxorubicin [20].
Similarly, 5-fluorouracil only can exceptionally cau-
se cardiac complications (angina pectoris or myocardial
infarction), but arrhythmia develops more frequently after
this drug [20].
H e a r t  - c h e m o t h e r a p y  a n d  r a d i o t h e r a p y
Only few publications have appeared as yet on the risk of
late damage to the cardiovascular system following ra-
diotherapy and anthracyclines or taxoids, although cardio-
toxic effects of both these drug groups have been well
known [16, 20, 21]. It is considered that breast cancer pa-
tients treated with doxorubicin and radiotherapy are at in-
creased risk for heart damage [12, 16, 20-22]. There are
publications indicating that high doses should be avoided
if combined treatment with radiotherapy is given to the
left breast or scar area [12, 20, 22].
In patients receiving combined treatment with doxo-
ribicin (total dose 300 mg/m2) and radiotherapy to the
left chest side, 2.6% cases of congestive heart failure we-
re found after a mean time of 6.5 years, while after radio-
therapy to the right chest side or no radiotherapy this
prevalence of cardiotoxicity was 0.3% [23]. In the retro-
spective study with M.D. Anderson Cancer Centre 1%
cardiotoxicity incidence was found after treatment with
doxorubicin 300 mg/m2 and 4% incidence after 450 mg/m2
[24]. In another study [23] the percent of patients with
acquired congestive heart failure after 7 years of follow-up
was: 0% after CMF, 0.8% after CMF with doxorubicin,
2.8% after chemotherapy and radiotherapy to left chest si-
de. Doxorubicin dose 75 mg/m2 administered in four che-
motherapy courses concomitantly with radiotherapy, or
doxorubicin dose 450 mg/m2 given sequentially with radio-
therapy increased cardiotoxicity risk [16].
Not all papers report increased frequency of cardiac
complications after radiotherapy and anthracyclines. Hen-
denbergh et al. [25] evaluated the toxic effects of sequen-
tial chemotherapy with radiotherapy in 231 patients rece-
iving sparing treatment with doxoribicin 180 mg/m2 total
dose, and cyclophosphamide, methotrexate and 5-fluoro-
uracil with prednisone. During 53 months of follow-up
no evidence of heart damage was observed, such as my-
ocardial infarction or congestive heart failure.
The follow-up of patients in the Danish study sho-
wed that correctly planned postoperative radiotherapy
combined with CMF chemotherapy caused no increase of
risk for ischaemic heart disease in 12 years of observation
[26]. Similar results were obtained in the Swedish study in
which no serious heart damage cases were noted after
radiotherapy in the group of 275 patients after a mean fol-
low-up time of 12 years [9].
In the present study six out of seven patients with
echocardiographic abnormalities received four courses
of epirubicin and four courses of CMF, the total dose of
epirubicin was 400 mg/m2.
Cardiotoxicity after chemotherapy may be manife-
sted as cardiomyopathy or congestive heart failure [14]. In
laboratory investigations, abnormalities are found in
ECG, LVEF decreased by 50% or more, perfusion defects
in coronary arteries, impaired left ventricular systolic and
diastolic function, coronary perfusion defects [11, 14, 27].
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The percent of patients with subclinical heart damage
are not known.
The gold diagnostic standard of evaluation of da-
mage caused by chemotherapy is radioisotope ventriculo-
graphy and /or myocardial biopsy, but echocardiography
is also useful [19, 20]. The patients are evaluated using cli-
nical classification of circulatory failure acc. to NYHA.
Despite the fact that the best method of evaluation of
cardiac toxicity after radiotherapy is perfusion scintigraphy
white after chemotherapy it is radioisotope ventriculo-
graphy, we used other methods, which were adapted to
the economical possibilities of Cancer Center in Warsaw.
In our study abnormal LVEF in echocardiography
was found in two patients: one after radiotherapy to right
chest side, the other after left chest side radiotherapy.
Both had received four courses of epirubicin and four
courses of CMF. No typical signs of radiotherapy-induced
damage were found in their case, such as segmental con-
tractility disturbances of anterior wall, septum or heart
apex, myocardial infraction or clinical symptoms of coro-
nary artery disease. The analysis of isodose distribution in
the heart excluded radiotherapy as the cause of the obse-
rved abnormalities. This small number of cases precluded
the possibility of analysis of combined treatment effects
after radiotherapy to right or left chest side.
No cardiotoxicity of life-threatening degree was no-
ted in our material, but subclinical cardiotoxicity was pre-
sent in five cases, and NYHA 2 clinical heart failure was
detected in two cases. Maybe after a longer follow-up
the percent of patients with late complications after com-
bined treatment will increase.
L u n g s
High resolution computed tomography (HRCT) is a relia-
ble method for evaluation of the degree of pulmonary
fibrosis after radiotherapy [28], allowing for the detec-
tion of slight fibrosis and tracking its evolution: progres-
sion or involution. The method is highly sensitive, and
usually detects lesions before they appear in conventional
chest X-ray examination. Pulmonary fibrosis after radio-
therapy develops with various frequency, but was reported
even in 90% of cases [28, 29]. Usually it produces no clini-
cal symptoms [30]. Fibrosis develops, most frequently, 3 to
18 months after radiotherapy [28, 31] and the most impor-
tant factor influencing its development is the volume of
lung tissue in radiation-covered area and radiation dose in
that area [30]. After postoperative radiotherapy or breast
conservative treatment with photons from oblique fields
pulmonary volume in radiation-covered area is closely
correlated with the parameter called central lung distan-
ce, which is expressed on radiogram in lateral projection
as the distance from the anterior lung border to posterior
border of the field. If this distance does not exceed 3 cm
the risk of lung damage is low [32]. Skoczylas et al. [33]
described the characteristics of apical fibrosis in patients
after radiotherapy and chemotherapy or hormonal thera-
py assessed by means of densitometry. They demonstra-
ted, after analysis of lung X-ray findings, that early pulmo-
nary changes appeared within six months after radiothe-
rapy and had, a tendency for regression, but late fibrosis
development after one year remaining most frequently
unchanged or rarely showing progression [33].
According to the classification of pulmonary fibrosis
in the paper of M. Overgaard et al. [8], in our material in
the second examination no changes were present in 24 pa-
tients (grade 0). In all patients with parietal changes (13
patients), small disseminated fibrosis foci were found
(grade 1). The fibrosis of grade 2, with medium intensity,
well visible, rather confluent fibrotic opacities with some
retraction of surrounding lung tissue, were observed only
in 4 of 22 cases with apical changes. Grade 3 (severe le-
sion, irregular, confluent, fibrotic lesions in the area expo-
sed to radiation, with high grade retraction of surrounding
lung tissue) was never seen. In accordance with the obse-
rvations of Skoczylas [33] concerning apical fibrosis after
photon therapy our results also indicated a tendency for
progression or stabilization of lesions in this pulmonary
region. A different pattern of changes was noted in parie-
tal fibrosis. These lesions were usually not progressing
and some of them undergo even regression after over
two years. This could have been due to a relatively low to-
tal dose and fractional radiation dose administered to
that area.
Conclusions
1. Postoperative radiotherapy as an element of com-
bined adjuvant treatment in breast cancer cases, ad-
ministered in conventional fractionated doses, cau-
ses no clinically significant lesions in the lungs and he-
art.
2. The analysis of the distribution of isodoses in the heart
showed that clinically important myocardial changes
observed in two patients were not connected with ra-
diotherapy. Probably they were connected with epiru-
bicin chemotherapy.
3. Correctly planned postoperative radiotherapy is a safe
therapeutic method causing no significant disturbances
of the functions of vital organs during a mean follow-
-up period of 33 months.
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